Cardiomyopathy of insulin resistance

Heart Failure Clinics

Volumn 2, Issue 1, 2006, Pages 13-23

  Witteles, Ronald M ^a   Fowler, Michael B ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; METOPROLOL; ROSIGLITAZONE; THIAZIDE DIURETIC AGENT; UNCOUPLING PROTEIN;

ADRENERGIC SYSTEM; APOPTOSIS; CARDIOMYOPATHY; CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLE; DISEASE COURSE; DRUG EFFECT; ENERGY METABOLISM; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; MYOCARDITIS; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PREVALENCE; PROGNOSIS; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; CARDIOMYOPATHY, DILATED; COMORBIDITY; ENERGY METABOLISM; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; SYMPATHETIC NERVOUS SYSTEM;

EID: 33644910442     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2005.11.007     Document Type: Review

References (136)

1. W.B. Kannel, M. Hjortland, and W.P. Castelli Role of diabetes in congestive heart failure: the Framingham study Am J Cardiol 34 1 1974 29 34
2. S.W. Zarich, and R.W. Nesto Diabetic cardiomyopathy Am Heart J 118 5 Pt 1 1989 1000 1012
3. L. Amato, G. Paolisso, and F. Cacciatore Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group Diabetes Metab 23 3 1997 213 218
4. A.G. Bertoni, A. Tsai, and E.K. Kasper Diabetes and idiopathic cardiomyopathy: a nationwide case-control study Diabetes Care 26 10 2003 2791 2795
5. R.I. Hamby, S. Zoneraich, and L. Sherman Diabetic cardiomyopathy JAMA 229 13 1974 1749 1754
6. L.M. Shapiro, A.P. Howat, and M.M. Calter Left ventricular function in diabetes mellitus. I: Methodology, and prevalence and spectrum of abnormalities Br Heart J 45 2 1981 122 128
7. L.M. Shapiro, B.A. Leatherdale, and M.E. Coyne Prospective study of heart disease in untreated maturity onset diabetics Br Heart J 44 3 1980 342 348
8. L.M. Shapiro, B.A. Leatherdale, and J. Mackinnon Left ventricular function in diabetes mellitus. II: Relation between clinical features and left ventricular function Br Heart J 45 2 1981 129 132
9. N. Suskin, R.S. McKelvie, and R.J. Burns Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure Eur Heart J 21 16 2000 1368 1375
10. E. Ingelsson, J. Sundstrom, and J. Arnlov Insulin resistance and risk of congestive heart failure JAMA 294 3 2005 334 341
11. K.K. Ho, J.L. Pinsky, and W.B. Kannel The epidemiology of heart failure: the Framingham Study J Am Coll Cardiol 22(4) Suppl A 1993 6A 13A
12. Y.T. Chen, V. Vaccarino, and C.S. Williams Risk factors for heart failure in the elderly: a prospective community-based study Am J Med 106 6 1999 605 612
13. J.S. Gottdiener, A.M. Arnold, and G.P. Aurigemma Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study J Am Coll Cardiol 35 6 2000 1628 1637
14. J. He, L.G. Ogden, and L.A. Bazzano Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study Arch Intern Med 161 7 2001 996 1002
15. W.B. Kannel, W.P. Castelli, and P.M. McNamara Role of blood pressure in the development of congestive heart failure. The Framingham study N Engl J Med 287 16 1972 781 787
16. D. Levy, M.G. Larson, and R.S. Vasan The progression from hypertension to congestive heart failure JAMA 275 20 1996 1557 1562
17. S. Kenchaiah, J.C. Evans, and D. Levy Obesity and the risk of heart failure N Engl J Med 347 5 2002 305 313
18. L. Wilhelmsen, A. Rosengren, and H. Eriksson Heart failure in the general population of men-morbidity, risk factors and prognosis J Intern Med 249 3 2001 253 261
19. W.B. Kannel, D. Levy, and L.A. Cupples Left ventricular hypertrophy and risk of cardiac failure: insights from the Framingham Study J Cardiovasc Pharmacol 10 Suppl 6 1987 S135 S140
20. P. Verdecchia, G. Reboldi, and G. Schillaci Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension Circulation 100 17 1999 1802 1807
21. A. Ilercil, R.B. Devereux, and M.J. Roman Associations of insulin levels with left ventricular structure and function in American Indians: the Strong Heart Study Diabetes 51 5 2002 1543 1547
22. J. Kemppainen, H. Tsuchida, and K. Stolen Insulin signalling and resistance in patients with chronic heart failure J Physiol 550 Pt 1 2003 305 315
23. P. Iozzo, P. Chareonthaitawee, and D. Dutka Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance Diabetes 51 10 2002 3020 3024
24. C. Iribarren, A.J. Karter, and A.S. Go Glycemic control and heart failure among adult patients with diabetes Circulation 103 22 2001 2668 2673
25. A.G. Bertoni, W.G. Hundley, and M.W. Massing Heart failure prevalence, incidence, and mortality in the elderly with diabetes Diabetes Care 27 3 2004 699 703
26. R.M. Witteles, W.H. Tang, and A.H. Jamali Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link J Am Coll Cardiol 44 1 2004 78 81
27. J.W. Swan, S.D. Anker, and C. Walton Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure J Am Coll Cardiol 30 2 1997 527 532
28. G. Paolisso, M.R. Tagliamonte, and M.R. Rizzo Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease Am J Cardiol 83 9 1999 1338 1344
29. J. Arnlov, L. Lind, and B. Zethelius Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up Am Heart J 142 4 2001 720 724
30. J.H. O'Keefe Jr, A. Magalski, and T.L. Stevens Predictors of improvement in left ventricular ejection fraction with carvedilol for congestive heart failure J Nucl Cardiol 7 1 2000 3 7
31. D.M. Kaye, B. Smirk, and C. Williams Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure Pharmacogenetics 13 7 2003 379 382
32. S. Hasegawa, H. Kusuoka, and K. Maruyama Myocardial positron emission computed tomographic images obtained with fluorine-18 fluoro-2-deoxyglucose predict the response of idiopathic dilated cardiomyopathy patients to beta-blockers J Am Coll Cardiol 43 2 2004 224 233
33. A. Shah, and R.P. Shannon Insulin resistance in dilated cardiomyopathy Rev Cardiovasc Med 4 Suppl 6 2003 S50 S57
34. H. Taegtmeyer Switching metabolic genes to build a better heart Circulation 106 16 2002 2043 2045
35. H. Taegtmeyer, P. McNulty, and M.E. Young Adaptation and maladaptation of the heart in diabetes: part I: general concepts Circulation 105 14 2002 1727 1733
36. M.E. Young, P. McNulty, and H. Taegtmeyer Adaptation and maladaptation of the heart in diabetes: part II: potential mechanisms Circulation 105 15 2002 1861 1870
37. L. Opie The heart: physiology and metabolism 1991 Raven Press New York
38. V.G. Davila-Roman, G. Vedala, and P. Herrero Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy J Am Coll Cardiol 40 2 2002 271 277
39. J.C. Osorio, W.C. Stanley, and A. Linke Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure Circulation 106 5 2002 606 612
40. P. Razeghi, M.E. Young, and T.C. Cockrill Downregulation of myocardial myocyte enhancer factor 2C and myocyte enhancer factor 2C-regulated gene expression in diabetic patients with nonischemic heart failure Circulation 106 4 2002 407 411
41. H. Taegtmeyer, R. Hems, and H.A. Krebs Utilization of energy-providing substrates in the isolated working rat heart Biochem J 186 3 1980 701 711
42. D.P. Brazil, and B.A. Hemmings Ten years of protein kinase B signalling: a hard Akt to follow Trends Biochem Sci 26 11 2001 657 664
43. M.A. Lawlor, and D.R. Alessi PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114 Pt 16 2001 2903 2910
44. D. Bonnet, D. Martin, and L. Pascale De Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children Circulation 100 22 1999 2248 2253
45. H.C. Chiu, A. Kovacs, and D.A. Ford A novel mouse model of lipotoxic cardiomyopathy J Clin Invest 107 7 2001 813 822
46. P.B. Corr, M.H. Creer, and K.A. Yamada Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation J Clin Invest 83 3 1989 927 936
47. B.N. Finck, X. Han, and M. Courtois A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content Proc Natl Acad Sci U S A 100 3 2003 1226 1231
48. M.J. Birnbaum Turning down insulin signaling J Clin Invest 108 5 2001 655 659
49. P.F. Kantor, M.A. Robertson, and J.Y. Coe Volume overload hypertrophy of the newborn heart slows the maturation of enzymes involved in the regulation of fatty acid metabolism J Am Coll Cardiol 33 6 1999 1724 1734
50. G.D. Lopaschuk, R.L. Collins-Nakai, and T. Itoi Developmental changes in energy substrate use by the heart Cardiovasc Res 26 12 1992 1172 1180
51. P.M. Barger, and D.P. Kelly Fatty acid utilization in the hypertrophied and failing heart: molecular regulatory mechanisms Am J Med Sci 318 1 1999 36 42
52. M.N. Sack, T.A. Rader, and S. Park Fatty acid oxidation enzyme gene expression is downregulated in the failing heart Circulation 94 11 1996 2837 2842
53. P. Razeghi, M.E. Young, and J.L. Alcorn Metabolic gene expression in fetal and failing human heart Circulation 104 24 2001 2923 2931
54. M.A. Martin, M.A. Gomez, and F. Guillen Myocardial carnitine and carnitine palmitoyltransferase deficiencies in patients with severe heart failure Biochimica et Biophysica Acta 1502 3 2000 330 336
55. B.N. Finck, J.J. Lehman, and T.C. Leone The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus J Clin Invest 109 1 2002 121 130
56. T. Shiomi, H. Tsutsui, and S. Hayashidani Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction Circulation 106 24 2002 3126 3132
57. A.N. Carley, L.M. Semeniuk, and Y. Shimoni Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist improves cardiac metabolism but not contractile function Am J Physiol Endocrinol Metab 286 3 2004 E449 E455
58. K. Hallsten, K.A. Virtanen, and F. Lonnqvist Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone Diabet Med 21 12 2004 1280 1287
59. L.S. Liu, H. Tanaka, and S. Ishii The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes Endocrinology 139 11 1998 4531 4539
60. R.J. Sidell, M.A. Cole, and N.J. Draper Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart Diabetes 51 4 2002 1110 1117
61. Y.T. Zhou, P. Grayburn, and A. Karim Lipotoxic heart disease in obese rats: implications for human obesity Proc Natl Acad Sci U S A 97 4 2000 1784 1789
62. E.D. Abel, H.C. Kaulbach, and R. Tian Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart J Clin Invest 104 12 1999 1703 1714
63. R. Liao, M. Jain, and L. Cui Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice Circulation 106 16 2002 2125 2131
64. Y. Minokoshi, C.R. Kahn, and B.B. Kahn Tissue-specific ablation of the GLUT4 glucose transporter or the insulin receptor challenges assumptions about insulin action and glucose homeostasis J Biol Chem 278 36 2003 33609 33612
65. R. Tian, and E.D. Abel Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis Circulation 103 24 2001 2961 2966
66. L.A. Nikolaidis, A. Sturzu, and C. Stolarski The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy Cardiovasc Res 61 2 2004 297 306
67. D.D. Belke, S. Betuing, and M.J. Tuttle Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression J Clin Invest 109 5 2002 629 639
68. P. Hu, D. Zhang, and L. Swenson Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload Am J Physiol Heart Circ Physiol 285 3 2003 H1261 H1269
69. P.K. Mazumder, B.T. O'Neill, and M.W. Roberts Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts Diabetes 53 9 2004 2366 2374
70. K. Dutta, D.A. Podolin, and M.B. Davidson Cardiomyocyte dysfunction in sucrose-fed rats is associated with insulin resistance Diabetes 50 5 2001 1186 1192
71. A.J. Davidoff, M.M. Mason, and M.B. Davidson Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments Am J Physiol Endocrinol Metab 286 5 2004 E718 E724
72. J. Ren, L.J. Dominguez, and J.R. Sowers Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Ca2 + transients in adult rat ventricular myocytes Diabetes 48 10 1999 2059 2065
73. J. Ren, L.J. Dominguez, and J.R. Sowers Troglitazone attenuates high-glucose-induced abnormalities in relaxation and intracellular calcium in rat ventricular myocytes Diabetes 45 12 1996 1822 1825
74. S. Neubauer, M. Horn, and M. Cramer Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy Circulation 96 7 1997 2190 2196
75. A.J. Murray, R.E. Anderson, and G.C. Watson Uncoupling proteins in human heart Lancet 364 9447 2004 1786 1788
76. L.H. Opie The metabolic vicious cycle in heart failure Lancet 364 9447 2004 1733 1734
77. S. Nunoda, A. Genda, and N. Sugihara Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus Heart Vessels 1 1 1985 43 47
78. T.J. Regan, M.M. Lyons, and S.S. Ahmed Evidence for cardiomyopathy in familial diabetes mellitus J Clin Invest 60 4 1977 884 899
79. E. Vitolo, S. Madoi, and C. Sponzilli Vectorcardiographic evaluation of diabetic cardiomyopathy and of its contributing factors Acta Diabetologica Latina 25 3 1988 227 234
80. A. Frustaci, J. Kajstura, and C. Chimenti Myocardial cell death in human diabetes Circ Res 87 12 2000 1123 1132
81. S.B. Liggett, N.M. Tepe, and J.N. Lorenz Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level Circulation 101 14 2000 1707 1714
82. K. Nonogaki New insights into sympathetic regulation of glucose and fat metabolism Diabetologia 43 5 2000 533 549
83. P. Hjemdahl Stress and the metabolic syndrome: an interesting but enigmatic association Circulation 106 21 2002 2634 2636
84. S.E. Downing, and J.C. Lee Effects of insulin on experimental catecholamine cardiomyopathy Am J Pathol 93 2 1978 339 352
85. T.R. Wallhaus, M. Taylor, and T.R. DeGrado Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure Circulation 103 20 2001 2441 2446
86. C. Morisco, G. Condorelli, and V. Trimarco Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes Circ Res 96 2 2005 180 188
87. N.H. Andersen, S.H. Poulsen, and H. Eiskjaer Decreased left ventricular longitudinal contraction in normotensive and normoalbuminuric patients with type II diabetes mellitus: a doppler tissue tracking and strain rate echocardiography study Clin Sci (Lond) 105 1 2003 59 66
88. N.H. Andersen, S.H. Poulsen, and P.L. Poulsen Left ventricular dysfunction in hypertensive patients with type 2 diabetes mellitus Diabet Med 22 9 2005 1218 1225
89. D. Vinereanu, E. Nicolaides, and A.C. Tweddel Subclinical left ventricular dysfunction in asymptomatic patients with type II diabetes mellitus, related to serum lipids and glycated haemoglobin Clin Sci (Lond) 105 5 2003 591 599
90. S. Cosson, and J.P. Kevorkian Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy? Diabetes Metab 29 5 2003 455 466
91. C.M. Schannwell, M. Schneppenheim, and S. Perings Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy Cardiology 98 1-2 2002 33 39
92. P. Poirier, P. Bogaty, and C. Garneau Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy Diabetes Care 24 1 2001 5 10
93. M. Zabalgoitia, M.F. Ismaeil, and L. Anderson Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus Am J Cardiol 87 3 2001 320 323
94. Z.Y. Fang, S. Yuda, and V. Anderson Echocardiographic detection of early diabetic myocardial disease J Am Coll Cardiol 41 4 2003 611 617
95. K. Mizushige, L. Yao, and T. Noma Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model Circulation 101 8 2000 899 907
96. S. Carlstrom, and T. Karlefors Haemodynamic studies on newly diagnosed diabetics before and after adequate insulin treatment Br Heart J 32 3 1970 355 358
97. T. Karlefors Haemodynamic studies in male diabetics Acta Medica Scandinavica Supplementum 449 1966 45 80
98. A. Vered, A. Battler, and P. Segal Exercise-induced left ventricular dysfunction in young men with asymptomatic diabetes mellitus (diabetic cardiomyopathy) Am J Cardiol 54 6 1984 633 637
99. S.Z. Duan, C.Y. Ivashchenko, and M.W. Russell Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice Circ Res 97 4 2005 372 379
100. J. Ren, M.F. Walsh, and M. Hamaty Augmentation of the inotropic response to insulin in diabetic rat hearts Life Sci 65 4 1999 369 380
101. R.S. Williams, T.F. Schaible, and J. Scheuer Effects of experimental diabetes on adrenergic and cholinergic receptors of rat myocardium Diabetes 32 10 1983 881 886
102. D.J. Stewart, P. Cernacek, and K.B. Costello Elevated endothelin-1 in heart failure and loss of normal response to postural change Circulation 85 2 1992 510 517
103. M. Yanagisawa, H. Kurihara, and S. Kimura A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 332 6163 1988 411 415
104. S. Sakai, T. Miyauchi, and T. Sakurai Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart Circulation 93 6 1996 1214 1222
105. P. Picard, P.J. Smith, and J.C. Monge Coordinated upregulation of the cardiac endothelin system in a rat model of heart failure J Cardiovasc Pharmacol 31 Suppl 1 1998 S294 S297
106. B. Pieske, B. Beyermann, and V. Breu Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium Circulation 99 14 1999 1802 1809
107. L.L. Yang, R. Gros, and M.G. Kabir Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice Circulation 109 2 2004 255 261
108. D. Fraccarollo, K. Hu, and P. Galuppo Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling Circulation 96 11 1997 3963 3973
109. T. Kubota, C.F. McTiernan, and C.S. Frye Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha Circ Res 81 4 1997 627 635
110. B. Bozkurt, S.B. Kribbs, and F.J. Clubb Jr Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats Circulation 97 14 1998 1382 1391
111. E.S. Chung, M. Packer, and K.H. Lo Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial Circulation 107 25 2003 3133 3140
112. P.R. Kalra, J.C. Moon, and A.J. Coats Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 85 2-3 2002 195 197
113. H. Itoh, K. Doi, and T. Tanaka Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor gamma Clin Exp Pharmacol Physiol 26 7 1999 558 560
114. G. Winkler, P. Lakatos, and F. Salamon Elevated serum TNF-alpha level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients Diabet Med 16 3 1999 207 211
115. J. Tuomilehto, J. Lindstrom, and J.G. Eriksson Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 344 18 2001 1343 1350
116. S.G. Wannamethee, A.G. Shaper, and I.J. Perry Smoking as a modifiable risk factor for type 2 diabetes in middle-aged men Diabetes Care 24 9 2001 1590 1595
117. W.C. Knowler, E. Barrett-Connor, and S.E. Fowler Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 6 2002 393 403
118. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) A randomised trial Lancet 353 9146 1999 9 13
119. The Beta-Blocker Evaluation of Survival Trial Investigators A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure N Engl J Med 344 22 2001 1659 1667
120. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 9169 1999 2001 2007
121. M. Packer, M.R. Bristow, and J.N. Cohn The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group N Engl J Med 334 21 1996 1349 1355
122. M. Packer, A.J. Coats, and M.B. Fowler Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 22 2001 1651 1658
123. M. Packer, G.V. Antonopoulos, and J.A. Berlin Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis Am Heart J 141 6 2001 899 907
124. G.L. Bakris, V. Fonseca, and R.E. Katholi Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial JAMA 292 18 2004 2227 2236
125. S. Ferrua, M. Bobbio, and E. Catalano Does carvedilol impair insulin sensitivity in heart failure patients without diabetes? J Card Fail 11 8 2005 590 594
126. S. Jacob, K. Rett, and M. Wicklmayr Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study J Hypertens 14 4 1996 489 494
127. P.A. Poole-Wilson, K. Swedberg, and J.G. Cleland Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial Lancet 362 9377 2003 7 13
128. J.E. Sanderson, S.K. Chan, and G. Yip Beta-blockade in heart failure: a comparison of carvedilol with metoprolol J Am Coll Cardiol 34 5 1999 1522 1528
129. B. Dahlof, R.B. Devereux, and S.E. Kjeldsen Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 9311 2002 995 1003
130. D.J. Freeman, J. Norrie, and N. Sattar Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study Circulation 103 3 2001 357 362
131. L. Hansson, L.H. Lindholm, and L. Niskanen Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial Lancet 353 9153 1999 611 616
132. M.A. Pfeffer, K. Swedberg, and C.B. Granger Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 362 9386 2003 759 766
133. S. Yusuf, P. Sleight, and J. Pogue Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 3 2000 145 153
134. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 23 2002 2981 2997
135. R.W. Nesto, D. Bell, and R.O. Bonow Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement for the American Heart Association and American Diabetes Association Circulation 108 23 2003 2941 2948
136. Attenuating insulin resistance as a therapeutic target in the management of heart failure. National Institutes of Health clinical research study (active). Bethesda (MD): US Department of Health, Education, and Welfare; 2005. NIH protocol # 03-H-0217